References
- Munoz N, Bosch FX, Castellsague X, Diaz M, de Sanjose S, Hammouda D, et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer. 2004;111:278–285.
- Giannimi SL, Hanon E, Moris P, Van Mechelen M, Morel S, Dessy F, et al. Enhanced humoral and memory B cellular immunity using HPV 16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine. 2006; 24:5937–5949.
- Hilleman MR. Overview of vaccinology with special reference to papillomavirus vaccines. J Clin Virol. 2000;19:79–90.
- Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Rotelli-Martins CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: Follow up from a randomized control trial. Lancet. 2006;376:1247–1255.
- Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: A randomized controlled trial. Lancet. 2004;364:757–765.
- Villa LL, Cost RL, Petta CA, Andrade RP, Ault KA, Giuliano AR, et al. Prophylactic quadrivalent human papillomavirus (types 6,11, 16, and 18) L1 virus-like particle vaccine in young women: A randomized double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 2005;6:271–278.
References
- Brodsky FM, Guafgliardi LE. The cell biology of antigen processing and presentation and presentation. Annu Rev Immunol. 1191;9:707–744.
- Osanto S. Vaccine trials for the clinician: Prospects for tumor antigens. Oncologist. 1997;2:284–299.
- Parham P. Antigen processing. Transporters of delight. Nature. (Lond.) 1900;348:674–675.
- Monaco J. A molecular model of MHC class-I-restricted antigen processing. Immunol Today. 1992;13:173–179.
- Townsend SE, Allison JP. Tumor rejection after direct constimulation of CD8+ T cells by B7-transfected melanoma cells. Science. (Washington, D.C.) 1993;259:368–370.
- Falk K, Rotzchke O. Consensus motifs and peptide ligands of MHC class I molecules. Semin Immunol. 1993;5:81–87.
- Falk K, Rotzchke O, Stevanovic J. Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature. (Lond.) 1991;351:290–294.
- Kast WM, Bronklhorst AM, DeWaal LP, Melief CJ. Cooperation between cytotoxic and helper T lymphocytes in protection against lethal Sendai virus infection. J Exp Med. 1986;164:723–738.
- Keene J, Forman J. Helper activity is required for the in vitro generation of cytotoxic T lymphocytes. J Exp Med. 1982;150:1134–1142.
- Raulet D, Bevan M. Helper T cells for cytotoxic T lymphocytes need not be region restricted. J Exp Med. 1982;155:1766–1784.
- Allison JP, Hurwitz AA, Leach Dr. Manipulation of co-stimulatory signals to enhance antitumor T-cell responses. Curr Opin Immunol. 1195;7:682–686.
- Tai T, Paulson JC, Cahan CD, et al. Ganglioside CM2 as a human tumor antigen (OFA-I-1). Proc Natl Acad Sci. USA 1983;80:5392–5396.
- Fitch FW, Laneki DW, Gajewski TF. T-cell mediated immune regulation: Help and suppression. In: Paul W, Nita E, eds. Fundamental Immunology. New York, NY: Raven Press; 1993;733–761.
- Zinkernagel R, Doherty P. MHC-restricted cytotoxic cell: Studies on the biological role of polymorphic major transplantation antigens determining T cell restriction-specificity, function and responsiveness. Adv Immunol. 1979;27:51–106.
- Grant EP, Rock KL. MHC class I-restricted presentation of exogenous antigen by thymic antigen-presenting cells in vitro and in vivo. J Immunol. 1992;148:13–18.
- Harding CV, Song R. Phagocytic processing of exogenous particulate antigens by macrophages for presentation by class I MHC molecules. J Immunol. 1994;153:4925–4933.
- Kovacsovic-Bankowski M, Rock KL. A phagosome-to-cytosol pathway for exogenous antigens presented on MHC class I molecules. Science. (Washington, D.C.) 1995;267:243–245.
- Rock KL, Gamble S, Rothstein L. Presentation of exogenous antigen with class I major histocompatibility complex molecules. Science. (Washington, D.C.) 1990; 249:918–921.
- Rock KL, Rothstein L, Gamble S. Characterization of antigen-presenting cells that present exogenous antigens in association with calls I MHC molecules. J Immunol. 1993;150:438–446.
- Tanaka H, Tanaka J, Kjaargaard J, Shu S. Depletion of CD4+ CD25+ regulatory cells augments the generation of specific immune T cells in tumor-draining lymph nodes. J Immunother. 2002;25(3):207–217.
- Chen W, Jin W, Hardegen N, Lei KJ, Li L, Marinos N, McGrady G, Wahl SM. Conversion of peripheral CD4+ CD25- naïve T cells to CD4+CD25+ regulatory T cells by TGF-β induction of transcription factor Foxp3. J Exp Med. 2003;198(12):1875–1886.
- Pawelec G, Koch S, Griesemann H, Rehbein A, Hahnel K, Gouttefangeas C. Immunosenescence, suppression and tumour progression. Cancer Immunol Immunother. 2006;55:981–986.
- Garrido F, Carera T, Concha A, Glew S, Ruiz-Cabello F, Stern PL. Natural history of HLA expression during tumour development. Immunol Today. 1993;14(1):491–499.
- Garrido F, Ruiz-Cabello F, Cabrera T, Perez-Villar JJ, Lopez-Botet M, Duggan-Keen M, Stern PL. Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol Today. 1997;18(2):89–95.
- Speiser DE, Lienard D, Rufer N, Rubio-Gudoy V, Rimoldi D, Lejeune F, Krieg AM, Cerottini JC, Romero P: Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest. 2005;115(3):739–746.
- Peng G, Guo Z, Kiniwa Y, Voo KS, Peng W, Fu T, Wang DY, Li Y, Wang HY, Wang RF: Toll-like receptor 8-mediated reversal of CD4+ regulatory T cells. J Clin Invest. 2005;309(5739):1380–1384.
- Dannull J, Su Z, Rizzieri D, Yang BK, Coleman D, Yancey D, Zhang A, Dahm P, Chao N, Gilboa E, Vieweg J. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest. 2005;115(12):3623–3633.
- Attia P, Maker AV, Haworth LR, Rogers-Freezeer L, Rosenberg SA. Inability of a fusion protein of IL-2 and diptheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lyphocytes in patients with melanoma. J Immunother. 2005; 28(6): 582–592.
- Phan GQ, Yang JC, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ, Restifo NP, Haworth LR, Seipp CA, Freezer LJ, Morton KE, et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA. 2003;100(14):8372–8377.
- MacLean GD, Miles DW, Rubens RD, Reddish MA, Longenecker BM. Enhancing the effect of THERATOPE STn-KLH cancer vaccine in patients with metastatic breast cancer by pretreatment with low-dose intravenous cyclophosphamide. J Immunother with Emphasis Tumor Immunol. 1996;19(4):309–316.
- Glaser M. Regulation of specific cell-mediated cytotoxic response against SV40-induced tumor associated antigens by depletion of suppressor T cells with cyclophosphamide in mice. J Exp Med. 1979;149(3):774–779.
- Mitchell MS, Kan-Mitchell J, Kempf RA, Harel W, Shau HY, Lind S. Active specific immunotherapy for melanoma: Phase 1 trial of allogeneic lysates and a novel adjuvant. Cancer Res. 1988;48(20):5883–5893.
- Velu T, Ramlau R, Quoix E, Pawlicki M, Pless M, Lena H, Levy E, Krzakowski M, Limacher J-M, Bizouarne N. A phase II study evaluating the clinical efficacy of TG4010 (MVA-MUC1-IL2) in association with chemotherapy in patients with non small cell lung cancer. American Society of Clinical Oncology (ASCO), Orlando, FL, USA (2005): Abstract 7132.
- Nowak AK, Robinson BW, Lake RA. Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors. Cancer Res. 2003; 63(15):4490–4496.
- Mitchell MS, Abrams J, Thompson JA, Kashan-Sabet M, DeConti RC, et al. Randomized trial of an allogeneic melanoma lysate vaccine with low-dose interferon alfa-2b compared with high-dose interferon alfa-2b for resected stage III cutaneous melanoma. J Clin Oncol. 2007;(25)15: 2078–2085.
- Knutson KL. GMK(progenics pharmaceuticals). Curr Opin Invest Drugs. 2002;3(1):159–164.
- Chapman PB, Morrisey D, Panageas KS, Willimas L, Lewis JJ, Isreal RJ, Hamilton WB, Livingston PO. Vaccination with bivalent G(M2) and G(D2) ganglioside conjugate vaccine: A trial comparing doses of G(D2)-keyhole limpet hemocyanin. Clin Cancer Res. 2000;6(12):4658–4662.
- Small EJ, Fratesi P, Reese DM, Strang G, Laus R, Peshwa MV, Valone FH. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol. 2000;18(23):3894–3903.
- Knutson KL. Technology evaluation: DCVax, Northwest biotherapeutics. Curr Opin Mol Ther. 2002; 4(4):403–407.
- Small EJ, Schellhammer PF, Higano CS, et al. Placebo-controlled phase III trial of immunologic therapy with Sipuleucel-T (ACP8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol. 2006;24:3089–94.
- Simons JW, Sacks N. Granulocyte-macrophage colony-stimulating factor-transduced allogeneic cancer cellular immunotherapy: The GVAX vaccine for prostate cancer. Urologic Oncology. 2006;24:419–24.
- Michael A, Ball G, Quatan N, et al. Delayed disease progression after allogeneic cell vaccination in hormone-resistant prostate cancer and correlation with immunologic variables. Clin Cancer Res. 2005;11:4469–78.
- Weng W-K, Czerwinski D, Timmerman J, Hsu FJ, Levy R. Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype. J Clin Oncol. 2004;22:4717–4724.
- Inoges S, Rodriguez-Calivillo M, Zabalegui N, de Cerio Lopez-Diaz A, Villanueava H, Soria E, et al. Clinical benefit associated with idiotype vaccination in patients with follicular lymphoma. J Natl Cancer Inst. 2006;98:1292–1301.
- Tokunaga N, Murakami T, Endo Y, Nishizaki M, Kagawa S, Tanaka N, Fujiwara T. Human monocyte-derived dendritic cells pulsed with wild-type p53 protein efficiently induced CTLs against p53 overexpressing human cancer cells. Clin Cancer Res. 2005;11(3):1312–1318.